Webinar: Resurrecting Antibody Genus Protection – Allowed Claims Through CDR-Scanning

New antibody patenting strategies, such as structure-based genus and means-plus-function claims, are reshaping how antibody genus claims are being written post Amgen v. Sanofi. Join us on Thursday, March 5, at 12 PM ET, as we discuss examples of antibody genus claims recently allowed by the USPTO based on these strategies.

This webinar will explore:

• New antibody claim strategies that provide a viable path forward for genus claims that align with current USPTO and case-law guidance on enablement and written description
• How comprehensive CDR-Scanning is being used to obtain genus claims based on the common structural feature of the antibody’s paratope (as described in Banik et al., 2025, Nature Biotechnology)
• Examples of antibody genus claim structures recently allowed by the USPTO